Pomanda estimates the enterprise value of GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED at £0 based on a Turnover of £0 and 0.6x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED at £0 based on an EBITDA of £-481.3m and a 4.34x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED at £0 based on Net Assets of £-1.1b and 2.3x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Glaxosmithkline Intellectual Property (no.3) Limited is a live company located in stevenage, SG1 2NY with a Companies House number of 11480952. It operates in the other professional, scientific and technical activities n.e.c. sector, SIC Code 74909. Founded in July 2018, it's largest shareholder is
glaxo group limited
with a 100% stake. Glaxosmithkline Intellectual Property (no.3) Limited is a young,
unknown sized company, Pomanda has estimated its turnover at
£0 with
unknown
growth in recent years.
Glaxosmithkline Intellectual Property (no.3) Limited Health Check
Pomanda's financial health check has awarded Glaxosmithkline Intellectual Property (No.3) Limited a 0.5 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 3 areas for improvement. Company Health Check FAQs
Health Rating0.5out of 5
0 Strong
1 Regular
3 Weak
Size
There is insufficient data available for this Key Performance Indicator!
Glaxosmithkline Intellectual Property (No.3) Limited's latest turnover from December 2023 is 0 and the company has net assets of -£1.1 billion. According to their latest financial statements, we estimate that Glaxosmithkline Intellectual Property (No.3) Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Turnover
Other Income Or Grants
Cost Of Sales
24,757,000
Gross Profit
-24,757,000
Admin Expenses
495,809,000
283,737,000
182,391,000
154,170,000
143,655,000
Operating Profit
-520,566,000
-283,737,000
-182,391,000
-154,170,000
-143,655,000
Interest Payable
67,787,000
11,445,000
996,000
837,000
2,245,000
Interest Receivable
748,000
531,000
37,000
Pre-Tax Profit
-587,605,000
-294,651,000
-183,350,000
-155,007,000
-145,900,000
Tax
137,534,000
57,017,000
37,207,000
26,118,000
27,721,000
Profit After Tax
-450,071,000
-237,634,000
-146,143,000
-128,889,000
-118,179,000
Dividends Paid
Retained Profit
-450,071,000
-237,634,000
-146,143,000
-128,889,000
-118,179,000
Employee Costs
54,010
51,127
48,866
47,574
Number Of Employees
1
1
1
1
1
EBITDA*
-481,250,000
-250,828,000
-162,010,000
-135,029,000
-114,318,000
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Tangible Assets
19,754,000
8,848,000
Intangible Assets
2,011,000,000
308,346,000
52,570,000
50,467,000
64,479,000
Investments & Other
2,663,000
13,621,000
Debtors (Due After 1 year)
16,824,000
9,877,000
4,424,000
Total Fixed Assets
2,013,663,000
338,791,000
62,447,000
54,891,000
64,479,000
Stock & work in progress
Trade Debtors
Group Debtors
269,000
68,098,000
19,355,000
Misc Debtors
187,621,000
67,650,000
9,054,000
5,331,000
36,695,000
Cash
misc current assets
140,000
2,232,000
total current assets
188,030,000
69,882,000
114,162,000
54,895,000
36,695,000
total assets
2,201,693,000
408,673,000
176,609,000
109,786,000
101,174,000
Bank overdraft
Bank loan
Trade Creditors
777,000
445,000
9,500,000
Group/Directors Accounts
3,193,409,000
929,738,000
179,500,000
other short term finances
253,000
6,447,000
2,082,000
754,000
2,609,000
hp & lease commitments
other current liabilities
54,864,000
49,459,000
568,327,000
346,600,000
18,639,000
total current liabilities
3,249,303,000
986,089,000
570,409,000
356,854,000
200,748,000
loans
hp & lease commitments
Accruals and Deferred Income
33,306,000
51,755,000
other liabilities
18,605,000
provisions
total long term liabilities
33,306,000
51,755,000
18,605,000
total liabilities
3,282,609,000
1,037,844,000
570,409,000
356,854,000
219,353,000
net assets
-1,080,916,000
-629,171,000
-393,800,000
-247,068,000
-118,179,000
total shareholders funds
-1,080,916,000
-629,171,000
-393,800,000
-247,068,000
-118,179,000
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Operating Activities
Operating Profit
-520,566,000
-283,737,000
-182,391,000
-154,170,000
-143,655,000
Depreciation
Amortisation
39,316,000
32,909,000
20,381,000
19,141,000
29,337,000
Tax
137,534,000
57,017,000
37,207,000
26,118,000
27,721,000
Stock
Debtors
103,416,000
-2,555,000
57,919,000
-7,585,000
36,695,000
Creditors
332,000
445,000
-9,500,000
9,500,000
Accruals and Deferred Income
-13,044,000
-467,113,000
221,727,000
327,961,000
18,639,000
Deferred Taxes & Provisions
Cash flow from operations
-459,844,000
-657,924,000
29,505,000
236,135,000
-104,653,000
Investing Activities
capital expenditure
-1,741,970,000
-268,931,000
-33,390,000
-13,977,000
-93,816,000
Change in Investments
-10,958,000
13,621,000
cash flow from investments
-1,731,012,000
-282,552,000
-33,390,000
-13,977,000
-93,816,000
Financing Activities
Bank loans
Group/Directors Accounts
2,263,671,000
929,738,000
-179,500,000
179,500,000
Other Short Term Loans
-6,194,000
4,365,000
1,328,000
-1,855,000
2,609,000
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
-18,605,000
18,605,000
share issue
-1,674,000
2,263,000
-589,000
interest
-67,039,000
-10,914,000
-959,000
-837,000
-2,245,000
cash flow from financing
2,188,764,000
925,452,000
-220,000
-200,797,000
198,469,000
cash and cash equivalents
cash
overdraft
change in cash
glaxosmithkline intellectual property (no.3) limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for glaxosmithkline intellectual property (no.3) limited. Get real-time insights into glaxosmithkline intellectual property (no.3) limited's credit score, group structure and payment trends.
Perform a competitor analysis for glaxosmithkline intellectual property (no.3) limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other young companies, companies in SG1 area or any other competitors across 12 key performance metrics.
Glaxosmithkline Intellectual Property (No.3) Limited currently has 7 directors.
The longest serving directors include
Mr Adam Walker (Jul 2018) and
Mr Jerome Andries (Jul 2018).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to glaxosmithkline intellectual property (no.3) limited.
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED. This can take several minutes, an email will notify you when this has completed.
glaxosmithkline intellectual property (no.3) limitedCompanies House Filings - See Documents
